World Conference on Lung Cancer (WCLC) 2020 - Virtual Presidential Symposium

08 August 2020 - 08 August 2020

Nivolumab-ipilimumab displays potential in malignant pleural mesothelioma

24 Sep 2020 by

For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.

Nivolumab-ipilimumab displays potential in malignant pleural mesothelioma

24 Sep 2020

Sintilimab-chemo improves PFS in advanced NSCLC

15 Sep 2020 by

Combining the anti-PD-1 antibody sintilimab with a pemetrexed-platinum chemotherapy regimen improved survival outcomes in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), interim analysis of the phase III ORIENT-11* trial from China showed.

Sintilimab-chemo improves PFS in advanced NSCLC

15 Sep 2020

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

08 Sep 2020 by

In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

08 Sep 2020